Results 51 to 60 of about 2,984 (199)

Suppression of CMV Infection with Letermovir in a Kidney Transplant Patient

European Journal of Case Reports in Internal Medicine, 2020
Infection with cytomegalovirus (CMV) with resistance to ganciclovir (GCV) is a therapeutic challenge in kidney transplant patients, because standard treatment options are nephrotoxic. We report the case of a kidney transplant recipient with GCV-resistant
Uta Köpf, Hans Ulrich Klehr, Anna-Maria Eis-Huebinger, Souhaib Aldabbagh, Christian Strassburg, Dominik Boes, Philipp Lutz   +6 more
doaj   +1 more source

Cytomegalovirus Prophylaxis versus Pre-emptive Strategy: Different CD4(+) and CD8(+) T Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation [PDF]

, 2021
Reconstitution of T cells after transplantation is a determinant of the long-term success of the procedure, and the correlation with T cell recovery and cytomegalovirus reactivation and disease is well known.
Candoni A., Cavallin M., De Marchi R., Facchin G., Fanin R., Gottardi M., Michelutti A., Patriarca F., Rosignoli C., Sperotto A., Stella R.   +10 more
core   +1 more source

Letermovir use for cytomegalovirus prophylaxis following lung transplantation: A single-center review

JHLT Open
Background: Cytomegalovirus (CMV) remains a major cause of infection following solid organ transplant and valganciclovir prophylaxis is the standard of care. However, valganciclovir-associated myelosuppression limits its tolerability and can require dose
Alyssa K. Mezochow, MD, MSc, Kevin D. He, MD, Kathryn Whitaker, MD, Emily Blumberg, MD, Maria M. Crespo, MD, Andrew Courtwright, MD, PhD   +5 more
doaj   +1 more source

Mendelian Randomization Identifies the Potential Causal Impact of Dietary Patterns on Circulating Blood Metabolites [PDF]

, 2021
Nutrition plays an important role in the development and progress of several health conditions, but the exact mechanism is often still unclear. Blood metabolites are likely candidates to be mediating these relationships, as their levels are strongly ...
Andres Metspalu, Andres Metspalu, Hanna-Kristel Valge, James F. Wilson, James F. Wilson, Krista Fischer, Krista Fischer, Nele Taba, Nele Taba, Nicola Pirastu, Tõnu Esko, Tõnu Esko   +11 more
core   +3 more sources

Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation

Therapeutic Advances in Hematology, 2021
Background: Letermovir prophylaxis is currently the standard of care for the prevention of cytomegalovirus (CMV) infections in allogeneic hematopoietic stem-cell transplantation (allo-HSCT).
Po-Hsien Li, Cheng-Hsien Lin, Yu-Hui Lin, Tsung-Chih Chen, Chiann-Yi Hsu, Chieh-Lin Jerry Teng   +5 more
doaj   +1 more source

Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients

Microbiology Spectrum, 2022
De novo mutations in the UL56 terminase subunit and its associated phenotypes were studied in the context of cytomegalovirus (CMV) transplant recipients clinically resistant to DNA-polymerase inhibitors, naive to letermovir.
Marta Santos Bravo, Valentin Tilloy, Nicolas Plault, Sonsoles Sánchez Palomino, María Mar Mosquera, Mireia Navarro Gabriel, Francesc Fernández Avilés, María Suárez Lledó, Montserrat Rovira, Asunción Moreno, Laura Linares, Marta Bodro, Sébastien Hantz, Sophie Alain, María Ángeles Marcos   +14 more
doaj   +1 more source

The Antifungal Drug Isavuconazole Inhibits the Replication of Human Cytomegalovirus (HCMV) and Acts Synergistically with Anti-HCMV Drugs [PDF]

, 2021
We recently reported that some clinically approved antifungal drugs are potent inhibitors of human cytomegalovirus (HCMV). Here, we report the broad-spectrum activity against HCMV of isavuconazole (ICZ), a new extended-spectrum triazolic antifungal drug.
Celegato, Marta, Gribaudo, Giorgio, Lepesheva, Galina I., Loregian, Arianna, Luganini, Anna, Mercorelli, Beatrice   +5 more
core   +1 more source

The Troll Is Weakened but Not yet Defeated: An Update on Cytomegalovirus Management in Transplantation From the International CMV Symposium 2025

Transplant Infectious Disease, EarlyView.
This review synthesizes discussions from the 2025 International CMV Symposium on translating three recently updated international guidelines into clinical practice across solid organ and hematopoietic stem cell transplantation, highlighting advances in risk‐stratified prevention, emerging therapies, immune monitoring, and persistent implementation ...
Camille N. Kotton, Martina Sester, Julian Torre‐Cisneros, The International CMV Symposium Faculty   +3 more
wiley   +1 more source

Hinge Region in DNA Packaging Terminase pUL15 of Herpes Simplex Virus: A Potential Allosteric Target for Antiviral Drugs [PDF]

, 2019
Approximately 80% of adults are infected with a member of the herpesviridae family. Herpesviruses establish life-long latent infections within neurons, which may reactivate into lytic infections due to stress or immune suppression.
Brown, Jeremy M., Brylinski, Michal, Coghill, Lyndon M., Naderi, Misagh, Rothschild, J. Ainsley, Thaljeh, Lana F.   +5 more
core   +5 more sources

European Recommendations for Transitioning the Care of Patients With Multiple Myeloma Treated With B‐Cell Maturation Antigen Bispecific Antibodies From Academic Hospitals to Community‐Based Centers and for Outpatient Step‐Up Dosing

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Safe outpatient delivery of B‐cell maturation antigen–targeting bispecific antibodies (BCMA‐BsAbs) in multiple myeloma (MM) is challenging, particularly during step‐up dosing (SUD). Standardized guidance for European community practice is limited.
María‐Victoria Mateos, Elena Zamagni, Massimo Gentile, Rachel Hall, Florence Lachenal, Mónica López Riñon, Rakesh Popat, Christof Scheid, Thomas Wolff, Isabel Perez‐Cruz, Mohamad Mohty   +10 more
wiley   +1 more source